Samer Choucair: Digitalization Is Reshaping the Investment Equation in Egypt’s Pharmaceutical Sector
Entrepreneur Samer Choucair said the expansion of Egypt’s digital pharmaceutical traceability system represents a structural transformation in how the sector is managed.
He noted that the shift from traditional printed information to a digital system linking every medicine package to a unique electronic identity will strengthen transparency and improve supply-chain efficiency, creating new opportunities for investors capable of adapting to regulatory transformation.
Samer Choucair explained that the gradual implementation of the new phase of the traceability system for locally manufactured products from August 2026, following its introduction for imported products in February, reflects a broader digitalization trend across emerging markets.
He emphasized that the measure does not abolish Egypt’s mandatory pricing system, but reorganizes oversight mechanisms and standardizes data relating to official prices and product movement throughout the market.
Choucair added that the transition comes at an important time for Egypt’s growing pharmaceutical sector.
The market was worth approximately EGP 422 billion in 2025, while pharmaceutical exports approached $1.3 billion, making stronger regulatory infrastructure essential to improving the sector’s appeal to domestic and foreign investors.
He noted that Egypt’s pharmaceutical market has built a strong production base covering more than 90% of essential domestic requirements and has become the world’s twenty-sixth-largest market.
The next phase, however, will require a greater ability to integrate technology into manufacturing, management, and supply chains.
Samer Choucair explained that the new traceability system assigns each pharmaceutical package a unique code connecting production, expiry, and pricing data to the Egyptian Drug Authority.
This makes it possible to monitor the product’s journey from the factory to the patient, strengthening efforts to combat illicit distribution and improve inventory management.
“This type of regulatory transformation in emerging markets tests the ability of capital to distinguish between companies building sustainable digital infrastructure and those treating digitalization merely as a temporary compliance cost,” Samer Choucair said.
“Capital allocation in such environments should focus on entities capable of converting operating data into a competitive advantage, whether through inventory management or access to export markets that require international traceability standards.”
Choucair emphasized that the new system could reduce regulatory-monitoring and product-recall costs while providing more accurate data on consumption patterns, demand levels, and shortages.
A market producing approximately four billion pharmaceutical packages annually will benefit from the ability to update information centrally without reprinting packaging whenever operating data changes.
He explained that this advantage is particularly important amid fluctuations in imported raw-material prices and exchange rates, as digitalization provides greater flexibility in managing product cycles and reducing operating waste.
Samer Choucair noted that institutional investors and asset managers will reassess Egyptian pharmaceutical companies according to their readiness for digital transformation.
Companies that invested early in production lines equipped with two-dimensional coding systems and electronic connectivity will be better positioned to benefit from the new phase.
He added that smaller companies without developed technical infrastructure may face additional compliance and modernization costs.
This could encourage further mergers and acquisitions or stronger partnerships with technology companies specializing in pharmaceutical-traceability solutions.
Choucair emphasized that Egyptian pharmaceutical exports will be among the principal beneficiaries of the development, particularly as international markets increasingly require serialization and traceability standards to ensure product quality.
Egypt’s objective of increasing pharmaceutical exports to $3 billion by 2030 is directly connected to the sector’s ability to strengthen confidence in locally manufactured products.
“Institutional investors in 2026 are assigning increasing importance to institutional quality in regulated sectors,” Samer Choucair said. “The ability to manage regulatory risk through digital systems is no longer an additional advantage; it has become a fundamental requirement for protecting profit margins.”
He explained that the digital transformation of the pharmaceutical sector is aligned with global investment trends across the digital economy and healthcare.
Investors increasingly regard regulatory reforms in emerging markets as indicators of a maturing investment environment and improving governance quality.
Samer Choucair noted that the sector’s principal investment opportunities include improving working-capital efficiency, reducing losses caused by fraud and counterfeiting, and using operating data to strengthen production and distribution decisions.
The system could also support future movement toward more flexible pricing mechanisms based on economic data while preserving consumer protection.
He explained that challenges remain, including the speed of full implementation across every stage of the supply chain, the modernization of warehouses and pharmacies, and the need to prevent operating bottlenecks during the transition.
Successful implementation will be decisive in achieving the expected economic benefits.
Choucair added that investment in Egypt’s pharmaceutical sector should focus not only on volume growth, but also on a transition toward higher-value products such as biologics and vaccines, alongside the localization of active pharmaceutical ingredients and reduced dependence on external inputs.
“Companies that connect their digital investments to a clear strategy for localizing active ingredients and developing value-added products will be best positioned to generate sustainable long-term returns for investors,” Samer Choucair said.
He emphasized that the next phase will bring a reassessment of investment portfolios connected to Egypt’s pharmaceutical sector based on innovation capacity, digital compliance, and management efficiency rather than solely on production volumes or current market share.
Concluding his remarks, Samer Choucair emphasized that the pharmaceutical traceability system represents an important step toward a more transparent and efficient medicines market.
Its successful implementation could strengthen Egypt’s position as a regional pharmaceutical-manufacturing hub and attract further foreign direct investment.
He concluded that the genuine test will be whether companies can transform regulatory change into sustainable long-term economic value.